Astrazeneca AZN is down 0.5% in pre-market trading, after it said on Friday that there would be a further delay to its Brilinta heart drug after the U.S. Food and Drug Administration asked for extra analysis.
It's the second time this year the potential blockbuster product has been delayed.
Market News and Data brought to you by Benzinga APIs© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
